FLASCO

FLASCO News

Janssen CarePathGeneral Resources

https://www.janssencarepath.com/hcp/general-resources Access support to help navigate payer processes Know Your State Interactive Tool — Provides information on affordability options for your patients at the state level. Supporting Appropriate Payer Coverage Decisions Brochure — Helps you understand the information that payers may require for your patient’s coverage of medically necessary drug therapies. Prior Authorization Considerations Checklist — Presents general information...

BRCA Resource

Merck and FLASCO share the ASCO triple aim of matching the right patient to the right drug at the right time and believe this project can further that objective. Merck/AstraZeneca developed and shared a non-branded electronic resource that can be utilized by providers and patients, in both English and Spanish, that highlights why BRCA testing...

FDA approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)

Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. More Information. January 8, 2020 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer  Hematology/Oncology (Cancer)...

FDA grants approval to fam-trastuzumab deruxtecan-nxki (ENHERTU®)

From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the...

CMS Update: POLIVY has a permanent J-code

Genentech is pleased to inform you that the Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code for POLIVY™ (polatuzumab vedotin-piiq). POLIVY received FDA approval on June 10, 2019. Effective January 1, 2020, the J-code is J9309 (Injection, polatuzumab vedotin-piiq, 1 mg). The POLIVY J-code Announcement Flash Card, which details the new...

POLIVY Access Solutions

The PDF below contains sample coding information. Please see full Prescribing Information.  Please feel free to contact the Genentech team with any questions or concerns about coding and billing. Contact a POLIVY Access Solutions Specialist at (888) 249-4918 Monday through Friday, 6 a.m. to 5 p.m. PT, or visit Genentech-Access.com/POLIVY. Correct coding is the responsibility of...

PADCEV™ Now FDA Approved

WHAT IS PADCEV? PADCEV (enfortumab vedotin-ejfv) is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used if you have received an immunotherapy medicine and also received a chemotherapy-containing platinum medicine....

taiho oncology

January 1, 2020, the Lonsurf Copay Assistance Program will transition to a new copay administrator

Starting January 1,2020, the Lonsurf Copay Assistance Program will transition to a new copay administrator.   It will require some administrative actions on the part of whomever processes the scripts, both refills of existing scripts and new scripts.     Currently enrolled, commercially insured eligible patients will move to the new program: Member ID # will remain...

FDA approved enzalutamide (XTANDI, Astellas Pharma Inc.)

FDA approved enzalutamide (XTANDI, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC). More Information. December 16, 2019 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer  Hematology/Oncology (Cancer) Approvals & Safety Notifications    https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications  

Guidelines for Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline

Edgardo S. Santos Castillero, M.D., FACP, Secretary of the Florida Society of Clinical Oncology (FLASCO), Founding Partner, Florida Precision Oncology R&C, FPO, a Division of 21st Century Oncology Thoracic and Head/Neck Cancer Programs, and Clinical Associate Professor at Charles E. Schmidt College of Medicine, Florida Atlantic University shared his appreciation of the opportunity provided by ASCO to him and his Co-Chairs...

New Standards/Guidelines to Dispense Oral Medications

Luis E. Raez, MD, FACP, FCCP, President of Florida Society of Clinical Oncology (FLASCO), Chief Scientific Officer & Medical Director of Memorial Cancer Institute, Memorial Health Care System and Clinical Professor of Medicine at the Herbert Wertheim College of Medicine, Florida International University participated in the Expert Panel created by the American Society of Clinical Oncology (ASCO) and the National Community Oncology Dispensing...

Info on accelerated approval for BRUKINSA

Please be aware NCCN has recently updated their Oncology Guidelines for Mantel Cell Leukemia (MCL) based on the accelerated approval for BRUKINSA. NCCN has provided BRUKINSA (zanubrutinib) in R/R MCL with a Level 2A Preferred evidence listing, comparable to other BTKi in the class. This is the link to the NCCN main website, https://www.nccn.org/professionals/physician_gls/default.aspx . 

Signatera Test to Assess Residual Disease

Signatera is a personalized, tumor informed circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) assessment and surveillance monitoring. Signatera’s unique assay design is optimized to detect low levels of ctDNA with high sensitivity and specificity earlier than current colorectal cancer (CRC) standard of care. Signatera recently received Medicare draft coverage for certain forms...

Outcome of BRCA Survey Project

In July 2019, the FLASCO Board of Directors approved a Survey Initiative on BRCA testing with Merck, FLASCO Diamond Elite Member. All FLASCO Members who treat patients with breast/ovarian cancer, including APPs, were asked to complete the survey.  The goal of the project was to identify the needs in order to increase awareness and utilization...

Florida Health

January – 2020 – National Radon Action Month Webinar Series

The Florida Department of Health is a partner in conducting four free webinars during the month of January 2020.  The webinars are intended to raise awareness and knowledge of radon, the leading environmental cause of lung cancer in the United States.  You have the ability to affect change as it pertains to reducing radon-induced lung...

astrazeneca

CALQUENCE® (acalabrutinib) Receives US FDA Approval for New Indication

The US Food and Drug Administration (FDA) has approved CALQUENCE® (acalabrutinib) capsules for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CALQUENCE for CLL was granted Breakthrough Therapy Designation by the FDA, and the approval was granted under the FDA’s Real Time Oncology Review (RTOR) and newly established...

FLASCO Advocating for Florida’s Cancer Patients Florida Blue Revises Tavalisse, Promacta, Nplate and Doptolet Coverage for Treatment of ITP

Prompted by a FLASCO Clinical Practice issue, Florida Blue has agreed to remove the requirement that the member has undergone splenectomy or has a contraindication to splenectomy from Florida Blue coverage policies for Tavalisse, Promacta, Nplate, and Doptelet.  The policy in question allowed coverage in the absence of splenectomy if the member has a contraindication...

BeiGene

Introducing BRUKINSA™ (zanubrutinib)—the new BTK inhibitor

FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage For Immediate Release: November 14, 2019 Today, the U.S. Food and Drug Administration granted accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma...

FDA Approved REBLOZYL® (luspatercept-aamt)

The US Food and Drug Administration has recently approved REBLOZYL® (luspatercept-aamt), the first and only erythroid maturation agent (EMA) indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require...

sandoz

NOW AVAILABLE: ZIEXTENZO (pegfilgrastim-bmez)

Sandoz Inc., a division of Novartis, is pleased to announce that Sandoz Inc. has received FDA approval for ZIEXTENZO (pegfilgrastim-bmez). As you may be aware, ZIEXTENZO, a biosimilar of Neulasta®, is a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs...

Upcoming Changes to Genentech Patient Foundation Enrollment Forms

As part of Genentech’s ongoing commitment to patient access and ensuring that patients and practices have a positive experience with Genentech, we constantly assess our processes to ensure they remain in the best interest of our practices and patients. Starting October 21st 2019, we will be launching a faster, more intuitive Genentech Patient Foundation enrollment...

Who’s Online

Profile picture of FLASCO